Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Enrollment initiated in study of Abraxane as first-line therapy
May 5th, 2005
American Pharmaceutical Partners, Inc., (APPX) announced that American BioScience, Inc., has initiated enrollment in a phase II study of Abraxane administered weekly in combination with Herceptin in first-line treatment of metastatic breast cancer. The study will be conducted by International Oncology Network (ION), the nation's premier, and largest, network of community-based oncologists and will include 20 ION sites. The open-label, non-randomized study will include 70 patients with locally advanced or metastatic breast cancer and will be led by principal investigator Barry C. Mirtsching, MD, director of the Center for Oncology Research &...
Source: Women's Health Weekly (2005-05-05)
|
